北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 法律意见书 二〇二五年八月 北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 法律意见书 致：北京英诺特生物技术股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京英诺特生物技术股份有 限公司（以下简称"英诺特"或"公司"）委托，就公司 2023 年限制性股票激励计 划（以下简称"激励计划"或"本激励计划"）相关事宜担任专项法律顾问，并就本 激励计划出具本法律意见书。 为出具本法律意见书，本所律师审阅了《北京英诺特生物技术股份有限公司 京英诺特生物技术股份有限公司 2023 年限制性股票激励计划实施考核管理办 法》（以下简称"《考核办法》"）、公司相关董事会会议文件以及本所律师认为需 要审查的其他文件，并通过查询政府部门公开信息对相关的事实和资料进行了核 查和验证。 为出具本法律意见书，本所律师根据有关法律、行政法规、规范性文件的规 定和本所业务规则的要求，本着审慎性及重要性原则对本激励计划的有关的文件 资料和事实进行了核查和验证。 -1- 对本法律意见书，本所律师作出如下声明： 提供了本所律师认为制作法律意见书所必需的原始书面材料、 ...

上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于博众精工科技股份有限公司 法律意见书 上海澄明则正律师事务所 上海市南京西路 1366 号恒隆广场二期 2805 室 电话：021-52526819 传真：021-52526089 www.cm-law.com.cn 上海澄明则正律师事务所 法律意见书 《上海证券交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）及 《科创板上市公司自律监管指南第4号——股权激励信息披露》（以下简称"《自 律监管指南》"）等有关法律、法规和规范性文件的规定以及《博众精工科技股 份有限公司章程》（以下简称"《公司章程》"），按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，现就根据公司2023年实施的《2023年限制性股票激励 计划》（以下简称"《激励计划》"或"本次激励计划"）授予价格调整（以下 简称"本次调整"）相关事项出具本法律意见书。 为出具本法律意见书，本所律师特作如下声明： 一、本所及经办律师依据《公司法》《证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及 本法律意见书出具日以前已经发生或 ...

Core Viewpoint - The legal opinion letter from Beijing Zhonglun Law Firm confirms that Changxin Bochuang Technology Co., Ltd. has completed the necessary approvals and authorizations for the adjustment of the grant price in its 2024 restricted stock incentive plan, in compliance with relevant laws and regulations [1][14]. Summary by Sections Approval and Authorization - The company has fulfilled the required approval and authorization procedures for the grant price adjustment, including passing relevant resolutions at board meetings [7][11]. - The resolutions include the approval of the draft and summary of the 2024 restricted stock incentive plan and the authorization for the board to handle related matters [8][12]. Adjustment Reasons - The adjustment of the grant price is necessitated by corporate actions such as capital reserve transfers, stock dividends, and other equity-related events that occurred between the announcement of the incentive plan and the vesting of the restricted stocks [11][13]. Adjustment Method and Results - The adjusted grant price for the 2024 restricted stock incentive plan is calculated as follows: P = P0 - V, where P0 is the original grant price of 13.21 RMB per share, and V is the dividend of 0.08 RMB per share, resulting in an adjusted price of 13.13 RMB per share [13]. - The adjustment is within the authorized scope and does not require further shareholder approval [12][14]. Information Disclosure Obligations - The company is required to disclose the resolutions from the board and supervisory board meetings regarding the grant price adjustment in a timely manner, in accordance with relevant laws and regulations [14]. - Continuous compliance with information disclosure obligations is necessary as the incentive plan progresses [14].

Core Viewpoint - The legal opinion from Beijing Jincheng Tongda (Shenyang) Law Firm confirms that the price adjustment for Yantai Ruichuang Micro-Nano Technology Co., Ltd.'s stock incentive plan has received necessary approvals and complies with relevant laws and regulations [1][11]. Summary by Sections Price Adjustment Approval and Authorization - The board of directors and the supervisory board of Yantai Ruichuang Micro-Nano Technology Co., Ltd. have approved the stock incentive plan and its related matters, ensuring no harm to the interests of the company and its shareholders [2][4]. Price Adjustment Details - The adjustment of the stock incentive plan's grant price is due to the company's capital actions, such as cash dividends, which necessitate a recalibration of the grant price [11]. - The new grant price is calculated as follows: P = P0 - V, where P0 is the original grant price, and V is the cash dividend per share. The adjusted price is 19.635 yuan per share after accounting for a cash dividend of 0.08 yuan [12]. Compliance and Conclusion - The legal opinion asserts that the price adjustment has been properly authorized and aligns with the provisions of the relevant laws, including the Company Law and Securities Law, as well as the company's articles of association [11][12].